John L Marshall, ASCO 2018 – PARP inhibitors for the personalized treatment of colorectal cancer
Editorial board member John L Marsahll from The Ruesch Center for the Cure of GI Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center in Washington, DC discusses unmet needs and major advances in the treatment of colorectal cancers, and how PARP inhibitors may play a role in treatment strategies in the near future.
1. What are the major unmet needs in the treatment of colorectal cancer? (0:11)
2. What have been the most important advances in colorectal cancer research in the past year? (0:41)
3. How is personalized medicine impacting the treatment of patients with colorectal cancer? (1:24)
4. What is the rationale for the use of PARP inhibitors in colorectal cancer? (2:14)
Speaker disclosures: John L Marshall has nothing to disclose in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
